Rosiglitazone, a Ligand to PPAR, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

Figure 5

Effect of rosiglitazone (RGZ) on angiotensin II and angiotensin-(1-7) production. Values obtained from aorta’s homogenate (a, c) and serum (b, d) from sham or aortic coarctated (AoCo) rats treated with vehicle (V), rosiglitazone (5mg/kg, RGZ), or RGZ + bisphenol A diglycidyl ether (120 mg/kg, RGZ+BADGE). The values represent the mean ± SEM (n=6 animals per group). One-way analysis of variance (ANOVA) post Tukey. ^∗P < 0.05 Sham-V vs. AoCo-V, ⁺P < 0.05 Sham-V vs. Sham-RGZ, ^%P < 0.05 Sham-RGZ vs. AoCo-RGZ, ^#P < 0.05 AoCo-V vs. AoCo-RGZ, and ^&P < 0.05 AoCo-RGZ vs. AoCo-RGZ+BADGE.

(a)

(b)

(c)

(d)